- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04755777
Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill
February 18, 2023 updated by: Erin Barreto, Mayo Clinic
Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill: a Multicenter Mixed-methods Study
The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
138
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
-
-
-
Florida
-
Gainesville, Florida, United States, 32610
- UF Health Shands
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Data will be obtained from ICU clinicians at three hospitals with distinct beta-lactam dosing and monitoring practices: Royal Brisbane and Women's Hospital in Queensland Australia, University of Florida Health Shands Hospital, Gainesville, Florida, United States, and the Mayo Clinic Hospital in Rochester, Minnesota, United States.
The sampling frame will include key clinician stakeholders likely to be involved with beta-lactam TDM in the intensive care unit (i.e., pharmacists, intensivists, infectious diseases experts, medical/surgical trainees, and advanced practice providers).
Description
Inclusion Criteria:
- Providers involved with beta-lactam TDM for critically ill patients
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of drug level testing recommended
Time Frame: Baseline
|
Indication of how many critically ill patients treated with beta-lactams should receive TDM.
|
Baseline
|
|
Nature of drug level testing recommended
Time Frame: Baseline
|
Indication of which types of critically ill patients treated with beta-lactams should receive TDM
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determinants of beta-lactam TDM implementation
Time Frame: Baseline
|
List of factors associated with successful beta-lactam TDM implementation
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ausman S, Boehmer K, et al. Open Forum Infectious Diseases. 2022;9(Supplement 2):ofac492.034.
- Barreto EF, Rule AD, Alshaer MH, Roberts JA, Abdul Aziz MH, Scheetz MH, Mara KC, Jannetto PJ, Gajic O, O'Horo JC, Boehmer KR. Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. Implement Sci Commun. 2021 Mar 24;2(1):34. doi: 10.1186/s43058-021-00134-9.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2020
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
February 10, 2021
First Submitted That Met QC Criteria
February 12, 2021
First Posted (Actual)
February 16, 2021
Study Record Updates
Last Update Posted (Estimate)
February 21, 2023
Last Update Submitted That Met QC Criteria
February 18, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-007528
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.